Agence Nationale de Sécurité du Médicament et des Produits de Santé

Tilray® Selected by French National Agency to Supply GMP-Certified Medical Cannabis Products in France

Retrieved on: 
Tuesday, January 26, 2021

Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis production, research, cultivation, and distribution, announced that it has been selected by the French National Agency for the Safety of Medicines and Health Products (ANSM) to supply Good Manufacturing Processes (GMP) certified medical cannabis products for experimentation in France.

Key Points: 
  • Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis production, research, cultivation, and distribution, announced that it has been selected by the French National Agency for the Safety of Medicines and Health Products (ANSM) to supply Good Manufacturing Processes (GMP) certified medical cannabis products for experimentation in France.
  • Tilray will supply GMP-produced medical cannabis products to serve patients in need for the duration of the French experiment (18-24 months), due to begin in the first quarter of 2021.
  • Tilray has received the necessary regulatory approvals to participate in the ANSM experimentation in France and will export medical cannabis products from its GMP-certified facility in Cantanhede, Portugal.
  • We are proud to be able to offer access to a variety of high-quality, pharmaceutical-grade medical cannabis products to the ANSM while supporting patients in need in France.

Covid-19 vaccination campaign safety : France rolls out the "Medication Shield" of Synapse Medicine

Retrieved on: 
Friday, January 15, 2021

BORDEAUX, France, Jan. 15, 2021 /PRNewswire/ -- Synapse Medicine, which was founded by public health physicians, rolls out its Medication Shield technology to increase the safety of the COVID-19 vaccination campaign in France, in collaboration with the regional pharmacovigilance centers (CRPVs) and the French National Agency for Medicines and Health Products Safety (ANSM).

Key Points: 
  • BORDEAUX, France, Jan. 15, 2021 /PRNewswire/ -- Synapse Medicine, which was founded by public health physicians, rolls out its Medication Shield technology to increase the safety of the COVID-19 vaccination campaign in France, in collaboration with the regional pharmacovigilance centers (CRPVs) and the French National Agency for Medicines and Health Products Safety (ANSM).
  • Because COVID-19 vaccines were developed in a brief period of time, it is crucial to ensure rigor and responsiveness in monitoring any possible side-effects.
  • In France, monitoring the safety of drugs, particularly vaccines, is carried out by the ANSM and the CRPVs.
  • Synapse Medicine has been working in collaboration with these health institutions for the past 18 months on a research project aiming to support the management of pharmacovigilance cases.

Covid-19 vaccination campaign safety : France rolls out the "Medication Shield" of Synapse Medicine

Retrieved on: 
Friday, January 15, 2021

BORDEAUX, France, Jan. 15, 2021 /PRNewswire/ -- Synapse Medicine, which was founded by public health physicians, rolls out its Medication Shield technology to increase the safety of the COVID-19 vaccination campaign in France, in collaboration with the regional pharmacovigilance centers (CRPVs) and the French National Agency for Medicines and Health Products Safety (ANSM).

Key Points: 
  • BORDEAUX, France, Jan. 15, 2021 /PRNewswire/ -- Synapse Medicine, which was founded by public health physicians, rolls out its Medication Shield technology to increase the safety of the COVID-19 vaccination campaign in France, in collaboration with the regional pharmacovigilance centers (CRPVs) and the French National Agency for Medicines and Health Products Safety (ANSM).
  • Because COVID-19 vaccines were developed in a brief period of time, it is crucial to ensure rigor and responsiveness in monitoring any possible side-effects.
  • In France, monitoring the safety of drugs, particularly vaccines, is carried out by the ANSM and the CRPVs.
  • Synapse Medicine has been working in collaboration with these health institutions for the past 18 months on a research project aiming to support the management of pharmacovigilance cases.

DGAP-News: ABIVAX: €36 million non-dilutive funding from Bpifrance for Abivax' ABX464 Covid-19 program

Retrieved on: 
Friday, May 15, 2020

Our gratitude also goes to ANSM, the ethics committee, clinicians and our partners that joined in this special effort.

Key Points: 
  • Our gratitude also goes to ANSM, the ethics committee, clinicians and our partners that joined in this special effort.
  • If miR-AGE is successful, we will work with regulators to make ABX464 available as quickly as possible, including rapid manufacturing scale-up.
  • Securing this financing from Bpifrance is a first major step towards funding Abivax for the next 18-24 months, preferably non-dilutive."
  • The funding consists of 20.1 million in grants and 15.9 million in refundable loans, which Abivax would repay after ABX464 reaches commercial stage.